Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings

Key Takeaways Eli Lilly is set to report Q3 earnings Oct. 30, with estimates at $16.01B for sales and $6.02 for EPS.Mounjaro and Zepbound remain key growth engines despite pricing and formulary headwinds.Lilly expands beyond GLP-1s with new drugs, M&A moves and pipeline diversification efforts.Eli Lilly and Company (LLY) will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $16.01 billion and $6.02 per share, respectively ...